Logo del repository
  1. Home
 
Opzioni

Sensory gating deficit assessed by P50/Pb middle latency event related potential in Alzheimer’s disease

CANCELLI I
•
PITTARO CADORE I
•
MERLINO G
altro
VALENTE, Mariarosaria
2006
  • journal article

Periodico
JOURNAL OF CLINICAL NEUROPHYSIOLOGY
Abstract
Sensory gating is defined as the brain's ability to inhibit repetitive and irrelevant incoming sensory stimuli and is supposed to be related to cholinergic transmission. Indeed, Alzheimer's disease (AD) is characterized by a cholinergic deficit that is believed to be involved in cerebral cortex hyperexcitability and short latency afferent inhibition deficit. Therefore, a sensory gating deficit may be supposed present in AD within the frame of cortex hyperexcitability and loss of cortex modulation of sensory inputs. The authors investigated whether a sensory gating deficit may be present in AD and whether this deficit may be related to the presence of neuropsychiatric symptoms (NPS) and reversed by donepezil treatment. Sensory gating was evaluated using a paired-stimulus auditory P50 event-related potential paradigm. Eighteen drug-naïve probable AD patients (mean age 76.1 years; SD 5.6 years; 13 females and 5 males) and 15 healthy elderly controls (mean age 74.2 years; SD 5.4 years; 10 females and 5 males) were recruited. Sensory gating was evaluated in AD patients before starting therapy and after 1 and 3 months of donepezil treatment. Auditory P50 sensory gating was impaired in AD patients but no correlation was found between gating deficit and NPS. Moreover, AD patients displayed increased P50 amplitude when compared with healthy elderly subjects. Donepezil treatment did not improve P50 sensory gating in AD patients but decreased P50 amplitude. Patients with AD displayed an augmented P50 amplitude, in accordance with previous studies, suggesting increased cortex excitability. Donepezil does not affect P50 sensory gating but reduces P50 amplitude. Donepezil may induce P50 amplitude reduction by means of enhanced dopamine release. Indeed, it has been demonstrated that donepezil induces dopamine release "in vitro." The findings suggest that AD patients have a sensory gating impairment but the link with both NPS and the cholinergic deficit is doubtful.
DOI
10.1097/01.wnp.0000218991.99714.ee
WOS
WOS:000240964400005
Archivio
http://hdl.handle.net/11390/879487
info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-33749381397
Diritti
closed access
Soggetti
  • Alzheimer's disease

  • Donepezil

  • Middle latency acoust...

  • Neuropsychiatric symp...

  • P50

  • Sensory gating

  • Physiology

  • Neurology

  • Neurology (clinical)

  • Physiology (medical)

Scopus© citazioni
44
Data di acquisizione
Jun 2, 2022
Vedi dettagli
Web of Science© citazioni
43
Data di acquisizione
Mar 11, 2024
Visualizzazioni
4
Data di acquisizione
Apr 19, 2024
Vedi dettagli
google-scholar
Get Involved!
  • Source Code
  • Documentation
  • Slack Channel
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your nstitution's web identity.

Need professional help?

The original creators of DSpace-CRIS at 4Science can take your project to the next level, get in touch!

Realizzato con Software DSpace-CRIS - Estensione mantenuta e ottimizzata da 4Science

  • Impostazioni dei cookie
  • Informativa sulla privacy
  • Accordo con l'utente finale
  • Invia il tuo Feedback